Recruitment Begins in Phase 1 Trial of C-CAR088 for Multiple Myeloma
A Phase 1 trial in China is…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
CLR 131 Significantly Extends Survival of Heavily Treated Multiple Myeloma Patients in Phase 1 Trial
Heavily treated multiple myeloma patients included in the first…
Ayala Partnering with Novartis on Investigational AL102 for Treatment of Multiple Myeloma
In a new agreement, Ayala Pharmaceuticals will work…
Revlimid Maintenance Extends Survival Without Disease Worsening in Myeloma Patients, Phase 3 Trial Shows
Long-term maintenance treatment with Revlimid (lenalidomide) significantly improves…
First Patient Treated with Phase 1 Trial Combo of Reolysin, Opdivo, and Kyprolis
A Phase 1 trial of the combination of…
Study Tracing Myeloma Progression from Precursor Conditions Seeks Participants
A study is recruiting participants to examine the molecular…
